Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Research|June 29, 2012
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibitionMatias Casás-Selves, Jihye Kim, Zhiyong Zhang, et al.Cancer Research|December 21, 2006
Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinomaSufi Mary Thomas, Neil E Bhola, Qing Zhang, et al.Anti-Cancer Drugs|September 1, 2017
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancerShannon C Leonard, Helen Lee, Daniel F Gaddy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2016
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR InhibitionHannah A Scarborough, Barbara A Helfrich, Matias Casás-Selves, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumorsDaniel C Chan, Keith A Earle, Tom L M Zhao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levelsBarbara A Helfrich, David Raben, Marileila Varella-Garcia, et al.Molecular Cancer Therapeutics|May 16, 2003
Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survivalClark M Whitehead, Keith A Earle, John Fetter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumorsSamir E Witta, Daniel L Gustafson, A Scott Pierson, et al.Cancer Research|January 21, 2006
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell linesSamir E Witta, Robert M Gemmill, Fred R Hirsch, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2016
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung CancerHui Yu, Cory Batenchuk, Andrzej Badzio, et al.Pageof 3